Three-month wait for local vaccines
Australians will have to wait at least another three months to be injected with the first locally produced COVID-19 vaccine, as manufacturer CSL says it will not ‘fast-track’ production.
Csl
Watkins, Hewson on board for Reserve Bank’s fight back
Alison Watkins and Carolyn Hewson have been appointed as members to the Reserve Bank board.
HIV, Covid and fake news a deadly cocktail
Putting the two biggest health crises in the past 30 years – HIV and COVID-19 – in the same sentence was never going to end well.
Risk on vaccine was too much: CSL
Hopes of bolstering lucrative royalties and licence revenue from the development of a homegrown COVID-19 vaccine have been dashed.
ASX extends losses as CSL setback weighs
Stocks at five-day low following wobble on Wall Street, as CSL lost 3pc after vaccine trials were halted and IGO jumped after a raising.
Harness the best of the crisis
The need for a robust, sustainably funded scientific community has never been stronger, says CSL chief Paul Perrault.
ASX slips lower with banks, CSL down
The ASX again slipped lower, with the big surprise being CSL’s hopes of producing a locally developed COVID-19 vaccine dashed.
CSL knew of ‘risk’ to vaccine trials
Researchers considered the potential for false HIV positives in the COVID-19 vaccine a ‘manageable risk’. But trials have now been halted.
ASX on seven-day winning streak
The ASX winning streak has continued for a seventh straight day, with health stocks and Commonwealth Bank among the winners.
Cochlear boss likes sound of new CSL plant
Cochlear’s CEO Dig Howitt says the federal government’s $1.8bn deal with CSL will build Australia’s competitive advantage in medical manufacturing.
CSL plans $1.8bn vaccine factory
CSL’s influenza vaccine business, Seqirus, struck a $1.8bn deal with the Morrison government to build the factory.
Melbourne scores major vaccine coup
A new $1.8 billion vaccine manufacturing plant is set to be built in Melbourne to help secure the nation against future pandemics and flu seasons.
New vaccine plant builds on our scientific strengths
The nation will be well placed to fight future pandemics.
Vaccine plant to supply nation
Southern hemisphere’s largest vaccine manufacturing plant to be built in Australia in a $1.8bn deal.
Biggest health stock ‘still underrated’
Paradice’s David Moberley is excited about the “game-changing” opportunities for Australia’s foremost health care stock.
Australia’s plasma monopoly is stifling biotech
Our company is on the cusp of commercialising a COVID-19 hyperimmune treatment, but we are being forced to source plasma from overseas.
CSL to mass-produce vaccine before trials
Australia’s biggest health company, CSL, will on Monday start manufacturing a COVID-19 vaccine as Melbourne’s iron curtain lifts.
MUA queries foreign crews
CSL has won federal approval to fly in dozens of foreign seafarers from Covid hotspot in the Philippines, despite local maritime workers being available.
Biotech taps Bosch to automate Covid test factory
Bosch Australia is undergoing a renaissance, returning to turning over $1bn a year and providing factory automation to Australia’s biggest medical companies.
With Covid uncured, CSL starts work on the next epidemic
Australia’s biggest health company CSL is working with the US government to protect the world’s biggest economy from another health shock.
CSL loses staff in raid
Australian medical groups are raiding the ranks of CSL – one of the country’s heavyweights in the biotechnology field.
Covid vaccine on track for mid-2021: CSL
Healthcare giant CSL still expects a COVID-19 vaccine to become available by the middle of next year despite the pausing of several high-profile trials.
Confidence up, but ASX finishes firmly lower
Consumer confidence hit a 3-month high, but the ASX finished firmly lower, snapping a 7-day winning streak.
ASX up 1% on CSL, BHP, CBA gains
Australia’s share market closed 1pc higher with gains from heavyweights CSL, BHP and CBA before the FOMC meeting.
Open up, this isn’t wartime, CEOs plead
Country’s largest companies, including CSL, BHP and Wesfarmers, warn continued lockdown will cause irreparable damage.
Rally builds to 1.1pc as travel names rebound
Shares closed at daily highs as miners and CSL lifted, while travel names gained ground and Jefferies highlighted market risk from China tensions.
ASX fights to 0.3pc gain on bank, BHP lift
The extension of Victoria’s lockdown weighed on Transurban, but did little to hamper recovery in the major banks, while the newest BNPL stock jumped 45pc.
CSL in deal for two Covid vaccines
CSL has struck a deal with the commonwealth to produce two coronavirus vaccines by early 2021, if trials are successful.
Vaccine could be ready by early next year
The Australian company that developed vaccines for the Spanish flu and swine flu will help to fast-track two potential COVID-19 cures.
ASX wipes $58bn as BHP, CSL slide
Share losses accelerated at the close, to mark the benchmark’s worst day since May 1, with more weakness to come in the US overnight.
Original URL: https://www.theaustralian.com.au/topics/csl/page/8